Biogenity
Biogenity is a Danish Contract Research Organisation that delivers end-to-end proteomics, metabolomics, transcriptomics, and multiomics services for pharmaceutical, biotech, food technology, and academic researchers worldwide via a quote-based, fee-for-service model.
- Company typePrivate
- Founded2018
- HeadquartersAalborg, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Biogenity does
Biogenity ApS is a privately held Contract Research Organisation (CRO) headquartered in Aalborg, Denmark, specialising in omics-based research and discovery services. Founded in 2018 by Kenneth Kastaniegaard (CEO, Ph.D. in protein chemistry and applied AI) and Louis Loeb (CCO, M.Sc.), the company delivers end-to-end workflows spanning sample preparation, mass spectrometry, data analysis, and biological interpretation for proteomics (LC-MS/MS and Olink PEA), metabolomics, transcriptomics, and multiomics studies. Technical depth includes deep proteome coverage exceeding 10,000 proteins in cell studies, 800-1,200 proteins in plasma, 15,000+ phosphorylation site identifications, and 50,000+ peptides in peptidomics discovery mode, leveraging partner laboratories equipped with Thermo Fisher Orbitrap Eclipse Tribrid, Orbitrap Exploris 480, and Q Exactive instruments. Proprietary software IP (BioSWITCH, filed/pending) is being developed with Innovation Fund Denmark support to track molecular signals in expression-based omics data for biomarker discovery.
The business model is a quote-based, fee-for-service professional services model with per-sample pricing of €45-€8,000, minimum 8-16 sample orders, and a free initial consultation to scope projects. The go-to-market is sales-led and direct: customers engage via website forms or outreach, receive tailored proposals, and are served globally from the Danish office while sample testing is conducted at partner laboratories. The customer base spans pharmaceutical and biotech companies (biomarker discovery, drug development), food technology firms (fermentation, alternative proteins, bioactive compounds), and academic research institutions across disease areas including Alzheimer's, cancer, and immune-mediated conditions.
Revenue mechanics are diversified across three primary verticals, supplemented by non-dilutive funding from EU Horizon Europe projects (EXIMIOUS, EXPOSIM) covering exposome and immune-mediated disease research, and an Innovation Fund Denmark Innobooster grant for the BioSWITCH algorithm. Strategic core partnerships with DTU Centre for Diagnostics (Olink proteomics), TAmiRNA (transcriptomics for multiomics), and Thermo Fisher-equipped laboratories create a multiomics stack, while the company employs a 'one tree planted per project' sustainability programme as a brand differentiator. AI/ML capabilities are applied to data analysis rather than as a standalone product, using machine- and deep-learning for diagnostic and prognostic modeling, explainable AI for biomarker interpretation, and neural networks for text mining in exposome research.
Biogenity firmographics
Firmographics- Name
- Biogenity
- Legal name
- Biogenity ApS
- Website
- https://biogenity.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Biogenity is a Danish Contract Research Organisation that delivers end-to-end proteomics, metabolomics, transcriptomics, and multiomics services for pharmaceutical, biotech, food technology, and academic researchers worldwide via a quote-based, fee-for-service model.
- Ownership category
- akta.pro rank
Biogenity industry classification
Industry- Product category
- Contract Research Services (Omics / Proteomics)
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Proteomics & Mass Spectrometry Services (HLAGANAB), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Biogenity is headquartered
LocationHeadquarters
- HQ city
- Aalborg
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Biogenity business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Omics Fee-for-Service: Per-sample pricing model for proteomics, metabolomics, transcriptomics, and multiomics analysis. Pricing varies based on sample type, depth of proteome coverage required, and specific workflows. Minimum sample requirements apply (8-16 samples). Complete workflows include sample preparation, mass spectrometry analysis, data analysis, and consultation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Sample-based pricing ranging from €45 to €8,000 per sample |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Biogenity product offering
Product offeringCore offering
Biogenity is a Contract Research Organisation that provides omics-based research and discovery services. The company offers end-to-end workflows covering sample preparation, mass spectrometry analysis, bioinformatics, and biological interpretation for proteomics, metabolomics, transcriptomics, and multiomics studies. Services are delivered on a fee-for-service, quote-based model to pharmaceutical, biotech, food technology, and academic research clients globally.
Differentiator
Problem solved
Functional benefit
Products and services
- Proteomics Services
- Metabolomics Services
- Transcriptomics Services
- Multiomics Services
- Data Analysis Services
- Olink Proteomics Workflows High-throughput multiplexed protein biomarker analysis using Olink Proximity Extension Assay (PEA) technology, analyzing 48-1,500 protein biomarkers from 1µL samples. Delivered in partnership with DTU Centre for Diagnostics, providing end-to-end Olink proteomics workflows for biomarker discovery.
Quantifiable outcome
- Deep proteome coverage: 10,000+ proteins in cell studies, 3,000 proteins from laser microdissected tissue
- +3 more outcomes
Companies that use Biogenity
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Biogenity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature4 records
Biogenity partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- DTU Centre for Diagnostics (Technical University of Denmark)corePartnership expands Biogenity's Olink proteomics service offerings. DTU provides specialized expertise in Olink sample analysis using the Olink Explore platform, while Biogenity delivers comprehensive data analysis, bioinformatics, and machine learning approaches. The collaboration creates an end-to-end workflow from sample to biological insight for researchers seeking diagnostic and prognostic markers.
- TAmiRNAcorePartnership enables multiomics workflows combining proteomics and transcriptomics. TAmiRNA, an Austrian biotech specializing in transcriptomics with focus on microRNA as diagnostic and therapeutic targets, complements Biogenity's proteomics services. Combining transcriptomics with proteomics data provides insight into molecular signals and biological responses.
- Thermo Fisher Scientific (Collaborating Laboratories)coreBiogenity collaborates with specialized proteomics laboratories equipped with the latest Thermo Fisher Scientific instruments including Orbitrap Eclipse Tribrid, Orbitrap Exploris 480, and Q Exactive mass spectrometers. These partnerships ensure access to state-of-the-art equipment for deep proteome coverage.
- One Tree PlantedminorEnvironmental partnership for sustainability initiative. Biogenity donates trees for every project delivered to support Amazon rainforest reforestation. Each project delivery results in a tree planting certificate for the customer.
- Eximious Project ConsortiumcoreEU-funded project that pioneered new ways of assessing the human exposome and its association with immune-mediated diseases. Biogenity contributed neural networks for identifying causal links between exposures and immune-related diseases. EXPOSIM project builds directly on EXIMIOUS findings.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Biogenity competitors and assessment
Company assessmentDirect peers
- Olink Holding: Provider of the Olink Proximity Extension Assay (PEA) platform used by Biogenity for high-multiplex protein biomarker analysis. Comparable as a proteomics biomarker discovery specialist; Biogenity partners with DTU for Olink access, making Olink both a technology partner and competitive reference point.
- Poochon Scientific: US-based proteomics CRO providing mass spectrometry-based proteomics and bioinformatics services to pharma, biotech, and academic customers. Comparable to Biogenity as a similarly sized proteomics CRO competing for the same project types and customer segments.
- Cell Signaling Technology (CST): Proteomics tools and services provider offering PTM-specific and pathway-focused antibody and mass spectrometry services. Comparable to Biogenity's phosphoproteomics and post-translational modification offerings, with overlapping pharma/biotech and academic customer base.
- SomaLogic: Proteomics biomarker discovery company offering high-plex protein measurement (SomaScan platform) with bioinformatics services to pharma and academic researchers. Comparable to Biogenity in biomarker-focused proteomics services and target customer base of clinical researchers and drug developers.
- Biognosys: Swiss proteomics CRO offering discovery and targeted proteomics services using both DDA and DIA mass spectrometry, with bioinformatics interpretation. Most directly comparable to Biogenity given similar technology stack, proteomics focus, and fee-for-service CRO model targeting pharma/biotech/academic researchers.
Broad incumbents
- Evotec: Global large-cap CRO/CDMO offering drug discovery, development, and manufacturing services including omics and biomarker capabilities. Comparable as a competing CRO with multi-omics offerings and enterprise pharma relationships, though at far greater scale and breadth than Biogenity.
- Eurofins Scientific: Large global testing services group with a life-sciences footprint including genomics, proteomics, and bioinformatics services. Comparable as a broad incumbent competing for similar omics service work, with substantially larger scale, geographic reach, and B2B infrastructure.
Others
- Thermo Fisher Scientific: Manufacturer of Orbitrap mass spectrometers and owner of Olink and Patheon, providing both the instruments used by Biogenity's partner labs and competing CRO services. Comparable as an enabling technology partner and ecosystem incumbent rather than a like-for-like competitor.
- Bruker Corporation: Mass spectrometry and proteomics instrumentation vendor offering timsTOF and related platforms commonly used in proteomics CRO workflows. Comparable as an adjacent equipment/infrastructure provider to the proteomics CRO ecosystem in which Biogenity operates.
Emerging players
- Seer: Proteomics technology company developing the Proteograph platform for deep, unbiased proteomics at scale. Comparable to Biogenity in targeting deep-proteome biomarker discovery, though Seer is a platform/tools company rather than a fee-for-service CRO.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Biogenity social profiles
Digital presenceBiogenity financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biogenity leadership team
Management profileNumber of profiles
Profiles3 records
Biogenity funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biogenity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biogenity
What does Biogenity do?
Biogenity is a Contract Research Organisation that provides omics-based research and discovery services. The company offers end-to-end workflows covering sample preparation, mass spectrometry analysis, bioinformatics, and biological interpretation for proteomics, metabolomics, transcriptomics, and multiomics studies. Services are delivered on a fee-for-service, quote-based model to pharmaceutical, biotech, food technology, and academic research clients globally.
Is Biogenity a public or private company?
Biogenity is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Biogenity founded?
Biogenity was founded in 2018. It employs 1 to 10 people.
Where is Biogenity based?
Biogenity is headquartered in Aalborg, Denmark, in the Europe region.
How does Biogenity make money?
One revenue line is on record: omics Fee-for-Service.
Who are Biogenity's main competitors?
Direct peers on record are Olink Holding, Poochon Scientific, Cell Signaling Technology (CST), SomaLogic and Biognosys. Broad incumbents are Evotec and Eurofins Scientific. Others are Thermo Fisher Scientific and Bruker Corporation. Seer is listed as an emerging player.
Does Biogenity have an API?
No public API is recorded for Biogenity.
What industry is Biogenity in?
Biogenity's product category is Contract Research Services (Omics / Proteomics). Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 54171 and its SIC code is 8731.